244 related articles for article (PubMed ID: 27586093)
1. Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.
Takahashi N; Tsujimoto T; Inoue K; Kishimoto M; Kajio H
J Diabetes Investig; 2016 Sep; 7(5):805-6. PubMed ID: 27586093
[TBL] [Abstract][Full Text] [Related]
2. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
[TBL] [Abstract][Full Text] [Related]
3. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
4. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
[TBL] [Abstract][Full Text] [Related]
5. [Effects of long-acting insulin degludec on type 2 diabetic hemodialysis patients with poor glycemic control].
Wada K; Wada Y; Tsuruoka S
Nihon Jinzo Gakkai Shi; 2015; 57(5):872-7. PubMed ID: 26387380
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
Ghosal S; Sinha B; Gangopadhyay KK
Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
[TBL] [Abstract][Full Text] [Related]
7. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
9. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
10. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard L; MacNeill G
Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
[TBL] [Abstract][Full Text] [Related]
13. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
[TBL] [Abstract][Full Text] [Related]
16. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
17. Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Rosenstock J; Blevins TC; Bergenstal RM; Morrow LA; Qu Y; Jacober SJ
J Diabetes; 2016 Jan; 8(1):166-9. PubMed ID: 26278063
[No Abstract] [Full Text] [Related]
18. Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study.
Gradišer M; Berković MC; Bilić-Ćurčić I
Diabetes Res Clin Pract; 2017 Jul; 129():144-147. PubMed ID: 28527305
[TBL] [Abstract][Full Text] [Related]
19. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
[TBL] [Abstract][Full Text] [Related]
20. Insulin degludec: The new standard long acting insulin analogue for people with type 1 diabetes? [Letter to the Editor].
Merchante-Alfaro AÁ; Pérez-Naranjo S; Abellán-Galiana P; Rubio-Puchol O
Endocr J; 2016 Apr; 63(4):411-2. PubMed ID: 26961339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
